Evidence map›Paper›PMID 25401220›Full record

ArticleDNA and cell biology2015

Novel cytoprotective inhibitors for apoptotic endonuclease G.

Dae Song Jang, Narsimha R Penthala, Eugene O Apostolov, Xiaoying Wang, Peter A Crooks, Alexei G Basnakian

Open access · greenAbstract read
In one paragraph

Article in DNA and cell biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. The Dual Regulation of Apoptosis by Flavivirus.Frontiers in microbiology · 2021
    Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Dae Song Jang1 Department of Pharmacology & Toxicology, University of Arkansas for Medical Sciences , Little Rock, Arkansas.
Narsimha R Penthala
Eugene O Apostolov
Xiaoying Wang
Peter A Crooks
Alexei G Basnakian
University of Arkansas for Medical Sciences · USCentral Arkansas Veterans Healthcare System · US

Funding

Understanding Hesitant AdoptersP20GM103429 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI Alan Tackett · 2012 to 2026
$60.9M
VIRULENCE MECHANISMS IN ESCHERICHIA COLIP20RR016460 · NCRR · UNIV OF ARKANSAS FOR MED SCIS · PI HENSLEY, LORI · 2001 to 2011
$33.1M
Development of Small Molecule Radiation SensitizersR01CA140409 · NCI · VANDERBILT UNIVERSITY · PI FREEMAN, MICHAEL L., KONJETI, SEKHAR RAJA · 2010 to 2014
$1.7M
Premortem enzymatic DNA damage in kidney injuryR01DK078908 · NIDDK · UNIV OF ARKANSAS FOR MED SCIS · PI BASNAKIAN, ALEXEI G · 2008 to 2012
$1.5M
Nuclease mechanisms in acute kidney injuryI01BX002425 · VA · CENTRAL ARKANSAS VETERANS HLTHCARE SYS · PI Alexei G Basnakian · 2015 to 2026
–
BLRD VA I01 BX002425NCI NIH HHS R01 CA140409NCRR NIH HHS P20 RR016460-11NIDDK NIH HHS R01 DK078908NIGMS NIH HHS P20 GM103429-11
6 · The paper itself

Abstract

Apoptotic endonuclease G (EndoG) is responsible for DNA fragmentation both during and after cell death. Previous studies demonstrated that genetic inactivation of EndoG is cytoprotective against various pro-apoptotic stimuli; however, specific inhibitors for EndoG are not available. In this study, we have developed a high-throughput screening assay for EndoG and have used it to screen a chemical library. The screening resulted in the identification of two potent EndoG inhibitors, PNR-3-80 and PNR-3-82, which are thiobarbiturate analogs. As determined by their IC₅₀s, the inhibitors are more potent than ZnCl₂ or EDTA. They inhibit EndoG at one or two orders of magnitude greater than another apoptotic endonuclease, DNase I, and do not inhibit the other five tested cell death-related enzymes: DNase II, RNase A, proteinase, lactate dehydrogenase, and superoxide dismutase 1. Exposure of natural EndoG-expressing 22Rv1 or EndoG-overexpressing PC3 cells rendered them significantly resistant to Cisplatin and Docetaxel, respectively. These novel EndoG inhibitors have the potential to be utilized for amelioration of cell injuries in which participation of EndoG is essential.

Indexed as

AnimalsAntineoplastic AgentsApoptosisCell LineCell Line, TumorCell SurvivalCisplatinDocetaxelDose-Response Relationship, DrugDrug ResistanceEndodeoxyribonucleasesEnzyme InhibitorsHumansKineticsMolecular StructureSmall Molecule LibrariesAntineoplastic AgentsCisplatinDocetaxelEndodeoxyribonucleasesendonuclease GEnzyme InhibitorsPNR-3-80PNR-3-82Small Molecule LibrariesTaxoidsThiobarbituratesthiobarbituric acid

Identifiers

PMID25401220
PMCPMC4308826
OpenAlexW2316714947

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.